Pimjetmi (pimicotinib): FDA approval, pivotal trial and safety

Approved
Type
New molecular entity · Oral
FDA-approved use
To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidityWording from FDA's list of novel approvals.
FDA review
Standard review
Company
Emd Serono
Application
NDA 220414
Specialty
Oncology

At a glance

Pimjetmi (pimicotinib) is an oral CSF-1 receptor inhibitor approved for adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity. In the phase 3 MANEUVER trial, the objective response rate at week 25 was 54% with pimicotinib versus 3% with placebo (absolute difference 51%, 95% CI 33-63, p<0.0001). Adverse events were mostly mild; the main grade 3 or 4 event was raised creatine phosphokinase.

What it is and how it works

Pimicotinib is a highly selective, potent inhibitor of the colony-stimulating factor-1 receptor (CSF1R). Blocking this receptor targets the signaling that drives TGCT growth. Surgery has been the usual treatment, and systemic options have been few. In the trial, investigators saw no liver injury of the cholestatic type, no drug-induced liver injury, and no loss of skin or hair color.

Pivotal trials

MANEUVER (part 1) NCT05804045

Design
International, randomized, double-blind, placebo-controlled phase 3 trial at 40 specialized hospitals in Asia, Europe, and North America. Randomization was 2:1, stratified by region (China vs non-China). Part 1 lasted 24 weeks, followed by an open-label extension in which placebo patients could cross over.
Patients
94 adults with unresectable, symptomatic TGCT (worse stiffness or worst pain of at least 4 on a 0-10 scale); 63 received pimicotinib and 31 placebo. 68% were female.
Compared with
Matching placebo given once daily
Primary endpoint
Objective response rate at week 25 by blinded independent review committee per RECIST 1.1, in the intention-to-treat population

Result

ORR was 54% (34 of 63) with pimicotinib and 3% (1 of 31) with placebo; absolute difference 51% (95% CI 33-63), p<0.0001.

Other results
The authors report clinically meaningful improvements in TGCT-related functional limitations and symptom burden. Specific secondary results are not given in the abstract.
Safety in the trial
Events were mainly mild. Pruritus, facial edema, rash, periorbital edema, and fatigue were noted. Grade 3 or 4 creatine phosphokinase increase occurred in 13% (8 of 63). Dose reductions occurred in 8% and discontinuation in 2%. No cholestatic liver toxicity, drug-induced liver injury, or skin or hair depigmentation was seen. Fatigue and arthralgia were most common with placebo.

Source: Xu H, et al. Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407:1072-1083.

EvidencePulse™

Ask about Pimjetmi

The question that opens in EvidencePulse

How does Pimjetmi (pimicotinib) compare with the alternatives (Surgical resection, Vimseltinib, Pexidartinib) for adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.

Ask in EvidencePulseFree to try, more with 2MM+.

Deep research is a core feature of 2MM Max.

Safety signals

There is no boxed warning. In MANEUVER, treatment-emergent adverse events were mainly mild. They included pruritus, facial edema, rash, periorbital edema, and fatigue, along with mostly asymptomatic laboratory abnormalities. The only grade 3 or 4 event in more than 10% of pimicotinib-treated patients was increased blood creatine phosphokinase, in 13% (8 of 63). Dose reductions occurred in 8% and discontinuations in 2%. The trial did not report cholestatic liver toxicity, drug-induced liver injury, or skin or hair depigmentation. Consult the full label for the complete warnings.

What it competes with

Surgical resection is the usual treatment for TGCT. Systemic CSF1R-directed therapy is an option when surgery is not suitable or may cause substantial morbidity.

  • Surgical resectionStandard approach for localized disease; less suitable when it risks functional limitation or severe morbidity.
  • VimseltinibOral CSF1R inhibitor approved for symptomatic TGCT not amenable to surgery.
  • PexidartinibCSF1R inhibitor for symptomatic TGCT; its use is limited by a risk of serious liver injury.
  • Radiation therapySometimes used as an adjunct or for recurrent disease in selected cases.

Bottom line for clinicians

Pimjetmi suits adults with symptomatic TGCT in whom surgery may cause worsening function or severe morbidity. The response advantage over placebo was large in a 24-week blinded phase, but the data come from a modest-sized trial (94 patients) with limited follow-up. Weigh the creatine phosphokinase elevations and edema-type events, and monitor accordingly.

Our coverage

We have not covered this drug yet.

Sources

  1. FDA approval letter
  2. Full prescribing information (FDA)
  3. FDA list of novel approvals
  4. Xu H, et al. Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407:1072-1083.
  5. ClinicalTrials.gov NCT05804045

Dosing, contraindications and full warnings are in the prescribing information.

New FDA approvals in your inbox

The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.

Your subscription opens securely in a new tab.

Last updated November 17, 2026 by 2 Minute Medicine.

For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.